niacinamide and ponatinib

niacinamide has been researched along with ponatinib in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (61.54)24.3611
2020's5 (38.46)2.80

Authors

AuthorsStudies
Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X1
Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F1
Fleischmann, M; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schmidt, V; Schnetzke, U; Scholl, S; Schrenk, KG1
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A1
Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F1
Lambrecht, AM; Larocque, EA; Naganna, N; Opoku-Temeng, C; Sintim, HO1
Becker, JR; Force, T; Galindo, CL; Glennon, MS; Gupte, M; Lal, H; Singh, AP; Umbarkar, P; Zhang, Q1
Antelope, O; Bowler, AD; Cayuela, JM; Clair, P; Deininger, MW; Druker, BJ; Eide, CA; Heinrich, MC; Kelley, TW; Kim, DW; O'Hare, T; Pomicter, AD; Qiang, W; Rea, D; Savage Stevens, SL; Schultz, AR; Senina, AV; Szankasi, P; Than, H; Tognon, CE; Tyner, JW; Vellore, NA; Yan, D; Zabriskie, MS1
Gao, H; Qiu, Y; Rao, Y; Sun, X; Sun, Y; Weng, Q; Yang, Y1
Cortes, J; Lang, F1
Batista, R; Bouscary, D; Cayuela, JM; Chapuis, N; Contejean, A; Decroocq, J; Goldwirt, L; Tamburini, J; Willems, L; Zerbit, J1
Alonso-Dominguez, JM; Alvarez-Larrán, A; Araujo, MC; Bitaube, RF; Boque, C; Carrascosa Mastell, P; Casado, LF; Cervero, C; Coll, AP; Cortes, M; Cuevas, B; De Las Heras, N; de Soria, VGG; Escola, A; Fernández, MJ; García-Gutiérrez, V; Garcia-Hernandez, C; García-Noblejas, A; Giraldo, P; Hernandez-Boluda, JC; Jiménez-Velasco, A; Lakhwani, S; Luna, A; Mora, E; Pérez-Encinas, M; Pérez-Lamas, L; Perez-Lopez, R; Ramila, E; Rosell, A; Ruiz Nuño, C; Sagüés, M; Salamanca, A; Sanchez-Guijo, F; Serrano, L; Steegmann, JL; Suarez-Varela, S; Vall-Llovera, F; Vega, MM; Vélez, P; Vera Goñi, JA; Villalon, L; Xicoy, B1
Alos, HC; Audira, G; Aventurado, CA; Hsiao, CD; Lai, YH; Lim, KH; Lin, HC; Roldan, MJM; Saputra, F; Tsai, GJ; Vasquez, RD1

Reviews

3 review(s) available for niacinamide and ponatinib

ArticleYear
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine

2014
Kinase Inhibitors in Multitargeted Cancer Therapy.
    Current medicinal chemistry, 2017, Volume: 24, Issue:16

    Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2017
Third-line therapy for chronic myeloid leukemia: current status and future directions.
    Journal of hematology & oncology, 2021, 03-18, Volume: 14, Issue:1

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Homoharringtonine; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Quinolines

2021

Other Studies

10 other study(ies) available for niacinamide and ponatinib

ArticleYear
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Blood, 2013, Apr-18, Volume: 121, Issue:16

    Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib

2013
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridazines; Retrospective Studies; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult

2017
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
    Toxicology, 2018, 02-15, Volume: 395

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib

2018
Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.
    ChemMedChem, 2018, 06-20, Volume: 13, Issue:12

    Topics: Alkynes; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Naphthyridines; Niacinamide; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Quinazolines

2018
Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
    Cardiovascular research, 2019, 04-15, Volume: 115, Issue:5

    Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Apoptosis; Cardiotoxicity; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Heart Diseases; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myocytes, Cardiac; Natriuretic Peptide, Brain; Niacinamide; Proof of Concept Study; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridazines; Rats; Signal Transduction; Zebrafish

2019
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Cancer cell, 2019, 10-14, Volume: 36, Issue:4

    Topics: Allosteric Regulation; Animals; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Targeted Therapy; Mutation; Niacinamide; Primary Cell Culture; Pyrazoles; Pyridazines

2019
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
    Journal of medicinal chemistry, 2020, 08-13, Volume: 63, Issue:15

    Topics: Antineoplastic Agents; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imidazoles; Models, Molecular; Niacinamide; Proteolysis; Pyrazoles; Pyridazines

2020
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:14

    Topics: Fusion Proteins, bcr-abl; Humans; Imidazoles; Niacinamide; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazoles; Pyridazines

2021
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Annals of hematology, 2022, Volume: 101, Issue:10

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Niacinamide; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Retrospective Studies

2022
Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.
    International journal of molecular sciences, 2022, Oct-03, Volume: 23, Issue:19

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monophenol Monooxygenase; Niacinamide; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Zebrafish

2022